JSPR
Jasper Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.71
+3.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +66.0%
- EBIT
- +41.3%
- EPS
- +73.5%
- Free cash flow
- +18.3%
- Operating cash flow
- +17.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +92.7%
- EPS
- +63.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -6.9%
- EBIT
- -5.6%
- Net income
- -6.4%
- EPS
- +19.2%
- Free cash flow
- -22.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026